Get the Stockscreener App
27.02
1.98%
0.46
Moderna Inc stock is traded at $27.02, with a volume of 6.71M.
It is up +1.98% in the last 24 hours and down -1.90% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$26.56
Open:
$26.92
24h Volume:
6.71M
Relative Volume:
0.63
Market Cap:
$10.46B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-3.0951
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+3.14%
1M Performance:
-1.90%
6M Performance:
-38.80%
1Y Performance:
-81.00%
1-Day Range:
$26.42
$27.40
1-Week Range:
$25.60
$27.85
52-Week Range:
$23.15
$158.82
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.04 | 10.35B | 3.14B | -3.36B | -4.03B | -8.73 |
|
ONC
Beone Medicines Ltd Adr
|
245.15 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.25 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.92 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
495.50 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna moves higher on FDA approval of new COVID-19 vaccine - Proactive financial news
Moderna's New Vaccine mNEXSPIKE Approved by FDA, Shares RiseNews and Statistics - IndexBox
FDA OKs new Moderna COVID-19 vaccine for 65+, others with conditions - AccuWeather
Moderna Stock Is Rising. A New Covid Vaccine Is Coming But Only for Some. - Barron's
Moderna Stock Climbs as FDA Approves New COVID-19 Vaccine - Investopedia
Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals - Benzinga
Douglas Lane & Associates LLC Buys 99,713 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Wins FDA Approval for Next-Gen COVID-19 Vaccine Despite ‘Investor Nervousness’ - BioSpace
Piper Sandler maintains overweight rating on Moderna stock - Investing.com
Moderna, Blueprint Medicines, Boeing - TradingView
Moderna Shares Rise on FDA Approval of Covid-19 Vaccine - marketscreener.com
Moderna gains as FDA nod for next-gen COVID-19 vaccine - Investing.com Canada
Moderna (MRNA) Rises 7% Following FDA Approval of New COVID-19 Vaccine - GuruFocus
Moderna Shares Gain On FDA Approval For New COVID-19 Vaccine - RTTNews
Moderna obtains FDA approval for mNEXSPIKE Covid-19 vaccine - World Pharmaceutical Frontiers
Moderna up 4% in premarket after FDA approval - breakingthenews.net
FDA Action Alert: Merck, Moderna, Gilead, Regeneron/Sanofi and More - BioSpace
Lansforsakringar Fondforvaltning AB publ Buys Shares of 107,880 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Gains FDA Approval for Latest COVID-19 Vaccine | MRNA Stock News - GuruFocus
FDA approves Moderna's new lower-dose COVID-19 vaccine - WPTZ
US authorities approve Moderna’s new COVID vaccine Statement - Daily Excelsior
FDA approves new Moderna COVID-19 vaccine - Axios
Moderna (MRNA) Gains FDA Approval for New COVID-19 Vaccine - GuruFocus
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it - CBS News
Investors Buy High Volume of Call Options on Moderna (NASDAQ:MRNA) - MarketBeat
FDA clears Moderna’s new COVID vaccine, but with limits - BioPharma Dive
Moderna wins narrower US approval for new COVID vaccine - Eagle-Tribune
Moderna Wins Narrower US Approval for New Covid Vaccine - MSN
mNEXSPIKE becomes Moderna's third FDA-approved product - The Pharma Letter
FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people - Endpoints News
Moderna wins FDA nod for next-gen COVID-19 shot - Seeking Alpha
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE - Lohud
Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by California State Teachers Retirement System - MarketBeat
FDA approves Moderna’s next-generation COVID vaccine for adults 65 or older - New York Post
FDA Covid Update: Moderna’s New mNEXSPIKE Vaccine Approved for Seniors - Deccan Herald
US FDA approves Moderna’s next-generation COVID vaccine for adults 65 or older - WKZO
US FDA approves Moderna's next-generation COVID vaccine for adults 65 or older - The Jerusalem Post
New COVID vaccine approved by US FDA: Here's all about it - Times of India
Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - Defense World
US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older - The Economic Times
Moderna Receives U.S. FDA Approval For Covid-19 Vaccine Mnexspike - marketscreener.com
Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE | MRNA Stock News - GuruFocus
Moderna Scores FDA Approval for Superior COVID Vaccine: 13.5% More Effective in 65+ Age Group - Stock Titan
Moderna, Inc. (MRNA) Reports Strong H5 Avian Flu Vaccine Data Despite HHS Funding Cut - MSN
US CDC keeps COVID vaccine option for healthy children - Reuters
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moderna Inc Stock (MRNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SAGAN PAUL | Director |
Mar 03 '25 |
Buy |
31.76 |
31,620 |
1,004,251 |
312,027 |
| Klinger Shannon Thyme | Chief Legal Officer |
Dec 09 '24 |
Sale |
44.68 |
529 |
23,637 |
20,446 |
1.76%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):